Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
Thursday, September 4, 2008 BiopharmaWatch Research 1 min read
Key Takeaway: Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+35%
120-day peak, hindsight
Typical move
2.6%
average across 15 past catalysts
Lead asset
VEGF Trap-Eye
Phase 1 · Diabetic Macular Edema
Full Press Release Details
Regeneron’s ARCALYST (rilonacept) Reduced Incidence of Gout Flares by 81 Percent in a Phase 2 Study in Gout Patients Initiating Urate-lowering Therapy Proportion of patients experiencing gout flares reduced from 45.2 percent to 14.6 percent.